Skip to main content

Table 2 Model results: lifetime horizon

From: Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

  Analysis 1 (UMEC vs TIO) Analysis 2 (UMEC vs GLY)
TIO UMEC GLY UMEC
Cumulative number of exacerbations
 Moderate 4.926 4.924 4.952 4.951
 Severe 1.659 1.608 1.636 1.604
 TOTAL 6.585 6.532 6.588 6.555
 Severe exacerbations PPPY 0.186 0.177 0.184 0.178
 Total exacerbations PPPY 0.740 0.718 0.740 0.726
Outcomes
 Accumulated LYs (undiscounted) 8.902 9.097 8.906 9.029
 Accumulated QALYs 5.003 5.121 5.038 5.139
Costs
 Accumulated costs (total) £12,800 £12,300 £11,800 £12,000
 Drug costs £3180 £2560 £2510 £2540
 Non-drug costs £9590 £9760 £9310 £9420
 Hospital costs £8800 £8960 £8550 £8640
 Outpatient/hospital/clinic costs £504 £514 £480 £486
 Physician visits (office, home, day or night) £288 £292 £288 £290
Incremental results (95% CI), UMEC vs comparator
 Incremental exacerbations   − 0.053 (− 0.171, 0.028)   − 0.033 (− 0.135, 0.017)
 Incremental cost   − £460 (− £645, − £240)   £132 (£12, £330)
 Incremental LYs   0.195 (0.069, 0.356)   0.124 (0.015, 0.281)
 Incremental QALYs   0.118 (0.055, 0.191)   0.101 (0.043, 0.179)
 ICER (QALY)   Dominant   £1310 (£284, £2060)
 ICER (LY)   Dominant   £1070 (£718, £1520)
  1. Cost and cost-effectiveness data are presented to three significant figures for values of three figures or more, and to the nearest pound for values rounding to less than 100
  2. CI confidence interval, GLY glycopyrronium, ICER incremental cost-effectiveness ratio, LY life year, PPPY per person per year, QALY quality-adjusted life year, TIO tiotropium, UMEC umeclidinium
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us